South Korea
· Delayed Price · Currency is KRW Komipharm International Statistics
Total Valuation
Komipharm International has a market cap or net worth of KRW 275.11 billion. The enterprise value is 310.14 billion.
| Market Cap | 275.11B |
| Enterprise Value | 310.14B |
Important Dates
The next estimated earnings date is Wednesday, November 6, 2024.
| Earnings Date | Nov 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Komipharm International has 69.65 million shares outstanding. The number of shares has decreased by -0.13% in one year.
| Shares Outstanding | 69.65M |
| Shares Change (YoY) | -0.13% |
| Shares Change (QoQ) | -0.33% |
| Owned by Insiders (%) | 40.08% |
| Owned by Institutions (%) | 3.16% |
| Float | 41.39M |
Valuation Ratios
The trailing PE ratio is 81.11.
| PE Ratio | 81.11 |
| Forward PE | n/a |
| PS Ratio | 5.39 |
| PB Ratio | 4.57 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 76.88, with an EV/FCF ratio of -430.87.
| EV / Earnings | 90.33 |
| EV / Sales | 6.04 |
| EV / EBITDA | 76.88 |
| EV / EBIT | n/a |
| EV / FCF | -430.87 |
Financial Position
The company has a current ratio of 1.04, with a Debt / Equity ratio of 68.52.
| Current Ratio | 1.04 |
| Quick Ratio | 0.58 |
| Debt / Equity | 68.52 |
| Debt / EBITDA | 10.83 |
| Debt / FCF | -60.68 |
| Interest Coverage | 0.26 |
Financial Efficiency
Return on equity (ROE) is 3.97% and return on invested capital (ROIC) is 0.48%.
| Return on Equity (ROE) | 3.97% |
| Return on Assets (ROA) | 0.42% |
| Return on Capital (ROIC) | 0.48% |
| Revenue Per Employee | 335.81M |
| Profits Per Employee | 22.44M |
| Employee Count | 153 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 2.19 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.19% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -27.19% |
| 50-Day Moving Average | 4,097.40 |
| 200-Day Moving Average | 4,233.88 |
| Relative Strength Index (RSI) | 42.09 |
| Average Volume (20 Days) | 90,773 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Komipharm International had revenue of KRW 51.38 billion and earned 3.43 billion in profits. Earnings per share was 48.70.
| Revenue | 51.38B |
| Gross Profit | 17.67B |
| Operating Income | 802.96M |
| Pretax Income | 2.69B |
| Net Income | 3.43B |
| EBITDA | 4.03B |
| EBIT | 802.96M |
| Earnings Per Share (EPS) | 48.70 |
Balance Sheet
The company has 12.14 billion in cash and 43.68 billion in debt, giving a net cash position of -31.54 billion or -452.80 per share.
| Cash & Cash Equivalents | 12.14B |
| Total Debt | 43.68B |
| Net Cash | -31.54B |
| Net Cash Per Share | -452.80 |
| Equity (Book Value) | 63.74B |
| Book Value Per Share | 865.25 |
| Working Capital | 2.24B |
Cash Flow
In the last 12 months, operating cash flow was -35.15 million and capital expenditures -684.66 million, giving a free cash flow of -719.80 million.
| Operating Cash Flow | -35.15M |
| Capital Expenditures | -684.66M |
| Free Cash Flow | -719.80M |
| FCF Per Share | -10.34 |
Margins
Gross margin is 34.38%, with operating and profit margins of 1.56% and 6.68%.
| Gross Margin | 34.38% |
| Operating Margin | 1.56% |
| Pretax Margin | 5.23% |
| Profit Margin | 6.68% |
| EBITDA Margin | 7.85% |
| EBIT Margin | 1.56% |
| FCF Margin | -1.40% |
Dividends & Yields
Komipharm International does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.13% |
| Shareholder Yield | 0.13% |
| Earnings Yield | 1.23% |
| FCF Yield | -0.26% |
Stock Splits
The last stock split was on August 17, 2023. It was a forward split with a ratio of 1.1006894.
| Last Split Date | Aug 17, 2023 |
| Split Type | Forward |
| Split Ratio | 1.1006894 |